Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France).
Details of the presentation are as follows:
|
Date |
Time |
Session |
||
|
Friday |
From 3:03 |
Selected Oral Communications Session
|
For more information about the event please visit : www.journeessfnp.fr/programme
About Pharnext
Pharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the treatment
of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug
status in Europe and the United States. PXT864 has generated positive
Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new
drug discovery paradigm: PLEOTHERAPY™. The Company identifies and
develops synergic combinations of repositioned drugs at new optimal
lower doses. These PLEODRUG™ offer several key advantages: efficacy,
safety and intellectual property, including several product or
composition of matter patents already granted. The Company is supported
by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180118005972/en/
Pharnext
René Goedkoop,+33 (0)1 41 09 22 30
Chief
Medical Officer
medical@pharnext.com
or
Investor
Relations (Europe)
MC Services AG
Anne Hennecke, +49 211
529252 22
anne.hennecke@mc-services.eu
or
Investor
Relations (U.S.)
Stern Investor Relations, Inc.
Matthew
Shinseki, +1 212 362 1200
matthew@sternir.com
or
Financial
Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56
88 11 15
sruiz@actifin.fr
or
Media
Relations (Europe)
ALIZE RP
Caroline Carmagnol
Aurore
Gangloff
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media
Relations (U.S.)
RooneyPartners
Marion Janic, +1 212 223
4017
mjanic@rooneyco.com
Permalink: http://www.businesswire.com/news/home/20180118005972/en
